 Krystal Biotech Inc NASDAQ: KRYS has announced positive topline results from the GEM-3 Phase 3 trial of investigational beremagene geperpavec B-VEC, Vyjuvek for dystrophic Epidermolysis Bullosa dystrophic EB. DEB is a genetic skin disorder affecting skin and nails that cause the skin to be very fragile and to blister easily. 